blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2780331

EP2780331 - PHARMACEUTICALLY ACTIVE PYRAZINE DERIVATIVES [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  24.02.2017
Database last updated on 29.07.2024
Most recent event   Tooltip12.10.2018Lapse of the patent in a contracting state
New state(s): AL		published on 14.11.2018  [2018/46]
Applicant(s)For all designated states
Sentinel Oncology Limited
Suite 52
23 Cambridge Science Park
Cambridge
Cambridgeshire CB4 0EY / GB
[2015/49]
Former [2014/39]For all designated states
Sentinel Oncology Limited
Suite 52 23 Cambridge Science Park Milton Road Cambridge
Cambridgeshire CB4 0EY / GB
Inventor(s)01 / BOYLE, Robert George
30 Catherine Street
Cambridge Cambridgeshire CB1 3AW / GB
02 / BOYCE, Richard Justin
Silas Cottage
Erratts Hill
Cowlinge
Newmarket Cambridgeshire CB8 9QG / GB
 [2014/39]
Representative(s)Hutchins, Michael Richard
Schlich
9 St Catherine's Road
Littlehampton, West Sussex BN17 5HS / GB
[2014/39]
Application number, filing date12810111.016.11.2012
[2016/16]
WO2012EP72917
Priority number, dateGB2011001979916.11.2011         Original published format: GB 201119799
[2014/39]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2013072502
Date:23.05.2013
Language:EN
[2013/21]
Type: A1 Application with search report 
No.:EP2780331
Date:24.09.2014
Language:EN
The application published by WIPO in one of the EPO official languages on 23.05.2013 takes the place of the publication of the European patent application.
[2014/39]
Type: B1 Patent specification 
No.:EP2780331
Date:20.04.2016
Language:EN
[2016/16]
Search report(s)International search report - published on:EP23.05.2013
ClassificationIPC:C07D241/26, C07D241/12, C07D403/12, C07D413/12, A61K31/4965, A61K31/497, A61P35/00
[2014/39]
CPC:
C07D241/26 (EP,US); A61K31/497 (EP,US); A61K31/5377 (EP,US);
A61K45/06 (US); A61P35/00 (EP); C07D401/12 (EP,US);
C07D403/12 (EP,US); C07D413/12 (EP,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2014/39]
Extension statesBA16.06.2014
ME16.06.2014
TitleGerman:PHARMAZEUTISCH WIRKSAME PYRAZIN-DERIVATE[2015/48]
English:PHARMACEUTICALLY ACTIVE PYRAZINE DERIVATIVES[2014/39]
French:DERIVES DE PYRAZINE PHARMACEUTIQUEMENT ACTIFS[2015/48]
Former [2014/39]PHARMAZEUTISCH AKTIVE PYRAZINDERIVATE
Former [2014/39]DÉRIVÉS PYRAZINE PHARMACEUTIQUEMENT ACTIFS
Entry into regional phase16.06.2014National basic fee paid 
16.06.2014Designation fee(s) paid 
16.06.2014Examination fee paid 
Examination procedure16.06.2014Examination requested  [2014/39]
22.01.2015Amendment by applicant (claims and/or description)
26.03.2015Despatch of a communication from the examining division (Time limit: M06)
17.09.2015Reply to a communication from the examining division
04.11.2015Communication of intention to grant the patent
24.02.2016Fee for grant paid
24.02.2016Fee for publishing/printing paid
24.02.2016Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  26.03.2015
Opposition(s)23.01.2017No opposition filed within time limit [2017/13]
Fees paidRenewal fee
26.11.2014Renewal fee patent year 03
28.12.2015Renewal fee patent year 04
Penalty fee
Additional fee for renewal fee
30.11.201504   M06   Fee paid on   28.12.2015
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU16.11.2012
AL20.04.2016
AT20.04.2016
BE20.04.2016
BG20.04.2016
CY20.04.2016
CZ20.04.2016
DK20.04.2016
EE20.04.2016
ES20.04.2016
FI20.04.2016
HR20.04.2016
IS20.04.2016
IT20.04.2016
LT20.04.2016
LV20.04.2016
MC20.04.2016
MK20.04.2016
NL20.04.2016
PL20.04.2016
RO20.04.2016
RS20.04.2016
SE20.04.2016
SI20.04.2016
SK20.04.2016
SM20.04.2016
TR20.04.2016
NO20.07.2016
GR21.07.2016
PT22.08.2016
MT16.11.2016
LU30.11.2016
[2018/46]
Former [2018/45]HU16.11.2012
AT20.04.2016
BE20.04.2016
BG20.04.2016
CY20.04.2016
CZ20.04.2016
DK20.04.2016
EE20.04.2016
ES20.04.2016
FI20.04.2016
HR20.04.2016
IS20.04.2016
IT20.04.2016
LT20.04.2016
LV20.04.2016
MC20.04.2016
MK20.04.2016
NL20.04.2016
PL20.04.2016
RO20.04.2016
RS20.04.2016
SE20.04.2016
SI20.04.2016
SK20.04.2016
SM20.04.2016
TR20.04.2016
NO20.07.2016
GR21.07.2016
PT22.08.2016
MT16.11.2016
LU30.11.2016
Former [2018/43]HU16.11.2012
AT20.04.2016
BE20.04.2016
BG20.04.2016
CY20.04.2016
CZ20.04.2016
DK20.04.2016
EE20.04.2016
ES20.04.2016
FI20.04.2016
HR20.04.2016
IS20.04.2016
IT20.04.2016
LT20.04.2016
LV20.04.2016
MC20.04.2016
MK20.04.2016
NL20.04.2016
PL20.04.2016
RO20.04.2016
RS20.04.2016
SE20.04.2016
SI20.04.2016
SK20.04.2016
SM20.04.2016
NO20.07.2016
GR21.07.2016
PT22.08.2016
MT16.11.2016
LU30.11.2016
Former [2018/38]HU16.11.2012
AT20.04.2016
BE20.04.2016
BG20.04.2016
CY20.04.2016
CZ20.04.2016
DK20.04.2016
EE20.04.2016
ES20.04.2016
FI20.04.2016
HR20.04.2016
IS20.04.2016
IT20.04.2016
LT20.04.2016
LV20.04.2016
MC20.04.2016
MK20.04.2016
NL20.04.2016
PL20.04.2016
RO20.04.2016
RS20.04.2016
SE20.04.2016
SI20.04.2016
SK20.04.2016
SM20.04.2016
NO20.07.2016
GR21.07.2016
PT22.08.2016
LU30.11.2016
Former [2018/30]HU16.11.2012
AT20.04.2016
BE20.04.2016
CY20.04.2016
CZ20.04.2016
DK20.04.2016
EE20.04.2016
ES20.04.2016
FI20.04.2016
HR20.04.2016
IS20.04.2016
IT20.04.2016
LT20.04.2016
LV20.04.2016
MC20.04.2016
MK20.04.2016
NL20.04.2016
PL20.04.2016
RO20.04.2016
RS20.04.2016
SE20.04.2016
SI20.04.2016
SK20.04.2016
SM20.04.2016
NO20.07.2016
GR21.07.2016
PT22.08.2016
LU30.11.2016
Former [2017/48]AT20.04.2016
BE20.04.2016
CZ20.04.2016
DK20.04.2016
EE20.04.2016
ES20.04.2016
FI20.04.2016
HR20.04.2016
IT20.04.2016
LT20.04.2016
LV20.04.2016
NL20.04.2016
PL20.04.2016
RO20.04.2016
RS20.04.2016
SE20.04.2016
SI20.04.2016
SK20.04.2016
SM20.04.2016
NO20.07.2016
GR21.07.2016
PT22.08.2016
LU30.11.2016
Former [2017/37]AT20.04.2016
BE20.04.2016
CZ20.04.2016
DK20.04.2016
EE20.04.2016
ES20.04.2016
FI20.04.2016
HR20.04.2016
IT20.04.2016
LT20.04.2016
LV20.04.2016
NL20.04.2016
PL20.04.2016
RO20.04.2016
RS20.04.2016
SE20.04.2016
SI20.04.2016
SK20.04.2016
SM20.04.2016
NO20.07.2016
GR21.07.2016
PT22.08.2016
Former [2017/11]AT20.04.2016
BE20.04.2016
CZ20.04.2016
DK20.04.2016
EE20.04.2016
ES20.04.2016
FI20.04.2016
HR20.04.2016
IT20.04.2016
LT20.04.2016
LV20.04.2016
NL20.04.2016
PL20.04.2016
RO20.04.2016
RS20.04.2016
SE20.04.2016
SK20.04.2016
SM20.04.2016
NO20.07.2016
GR21.07.2016
PT22.08.2016
Former [2017/10]AT20.04.2016
BE20.04.2016
CZ20.04.2016
DK20.04.2016
EE20.04.2016
ES20.04.2016
FI20.04.2016
HR20.04.2016
IT20.04.2016
LT20.04.2016
LV20.04.2016
NL20.04.2016
PL20.04.2016
RO20.04.2016
RS20.04.2016
SE20.04.2016
SK20.04.2016
NO20.07.2016
GR21.07.2016
PT22.08.2016
Former [2017/09]AT20.04.2016
BE20.04.2016
CZ20.04.2016
DK20.04.2016
EE20.04.2016
ES20.04.2016
FI20.04.2016
HR20.04.2016
IT20.04.2016
LT20.04.2016
LV20.04.2016
NL20.04.2016
PL20.04.2016
RO20.04.2016
RS20.04.2016
SE20.04.2016
NO20.07.2016
GR21.07.2016
PT22.08.2016
Former [2017/07]AT20.04.2016
BE20.04.2016
DK20.04.2016
ES20.04.2016
FI20.04.2016
HR20.04.2016
IT20.04.2016
LT20.04.2016
LV20.04.2016
NL20.04.2016
PL20.04.2016
RS20.04.2016
SE20.04.2016
NO20.07.2016
GR21.07.2016
PT22.08.2016
Former [2017/03]AT20.04.2016
BE20.04.2016
ES20.04.2016
FI20.04.2016
HR20.04.2016
IT20.04.2016
LT20.04.2016
LV20.04.2016
NL20.04.2016
PL20.04.2016
RS20.04.2016
SE20.04.2016
NO20.07.2016
GR21.07.2016
PT22.08.2016
Former [2016/52]AT20.04.2016
ES20.04.2016
FI20.04.2016
HR20.04.2016
LT20.04.2016
LV20.04.2016
NL20.04.2016
PL20.04.2016
RS20.04.2016
SE20.04.2016
NO20.07.2016
GR21.07.2016
PT22.08.2016
Former [2016/51]AT20.04.2016
ES20.04.2016
FI20.04.2016
HR20.04.2016
LT20.04.2016
LV20.04.2016
NL20.04.2016
PL20.04.2016
RS20.04.2016
NO20.07.2016
GR21.07.2016
PT22.08.2016
Former [2016/50]AT20.04.2016
ES20.04.2016
FI20.04.2016
HR20.04.2016
LT20.04.2016
LV20.04.2016
NL20.04.2016
PL20.04.2016
RS20.04.2016
NO20.07.2016
Former [2016/49]FI20.04.2016
LT20.04.2016
NL20.04.2016
PL20.04.2016
NO20.07.2016
Former [2016/46]LT20.04.2016
NO20.07.2016
Cited inInternational search[AD]WO2005072733  (MILLENNIUM PHARM INC [US], et al) [AD] 1-17 * pages 15-24; claims 1,17-23 *;
 [AD]WO2006014359  (ICOS CORP [US], et al) [AD] 1,15,16 * claims 1,2,5,6,13-16 *;
 [AD]WO2006021002  (ICOS CORP [US], et al) [AD] 1,15,16 * claims 1,5,6,11-13,17,18 *;
 [AD]WO02070494  (ICOS CORP [US]) [AD] 1,15,16 * claim 28 * * page 166, compound 328 * * abstract *;
 [ADP]WO2011141716  (SENTINEL ONCOLOGY LTD [GB], et al) [ADP] 1-17 * pages 70-72 * * pages 119,120 * * claim - *
by applicantWO2010149394
 WO03010444
 WO2005072733
 US2005215556
 WO02070494
 WO2006014359
 WO2006021002
 WO2010118390
    - CLIN, CAN. RES., (2007), vol. 13, no. 7
    - HAHN ET AL., "Rules for making human tumor cells", N. ENGL. J. MED., (2002), vol. 347, pages 1593 - 603
    - HOLLSTEIN ET AL., "p53 mutations in human cancers", SCIENCE, (1991), vol. 253, pages 49 - 53
    - CLIN. CANCER RES., (2010), vol. 16, page 376
    - JOURNAL OF NEUROSURGERY, (2004), vol. 100, page 1060
    - BIOORG. MED. CHEM. LETT., (2006), vol. 16, pages 421 - 6
    - NAT. CELL. BIOL., (200502), vol. 7, no. 2, pages 195 - 20
    - CLIN. CANCER RES., (2010), vol. 16, page 2076
    - CANCER RES., vol. 66, no. 16
    - BLOOD., (20080915), vol. 112, no. 6, pages 2439 - 2449
    - BLOOD., (20050215), vol. 105, no. 4, pages 1706 - 16
    - MOL. CANCER THER., (200503), vol. 4, no. 3, pages 457 - 70
    - BLOOD., (20110210), vol. 117, no. 6, pages 1947 - 57
    - NATURE, (2006), vol. 444, no. 7, pages 756 - 760
    - BIOCHEM. BIOPHYS. RES. COMMUN., (20110304), vol. 406, no. 1, pages 53 - 8
    - CANCER RESEARCH, (2009), vol. 89, page 8652
    - NATURE, (2008), no. 8, pages 180 - 192
    - CELL CYCLE, (2010), vol. 9, no. 13, page 2502
    - MOLECULAR CANCER, (2009), vol. 8, page 24
    - CANCER SCIENCE, (2011), vol. 102, page 882
    - P. HEINRICH STAHL (EDITOR), CAMILLE G. WERMUTH (EDITOR), Pharmaceutical Salts: Properties, Selection, and Use, HARDCOVER, (200208), page 388
    - BERGE ET AL., "Pharmaceutically Acceptable Salts", J. PHARM. SCI., (1977), vol. 66, pages 1 - 19
    - JERRY MARCH, Advanced Organic Chemistry, 4th Edition,, JOHN WILEY & SONS, (1992), pages 109 - 114
    - CAHN; INGOLD; PRELOG, ANGEW. CHEM. LNT. ED. ENGL., (1966), vol. 5, pages 385 - 415
    - JEREMIAH P. FREEMAN, Organic Syntheses, JOHN WILEY, (1995), vol. 1-8
    - SHEEHAN ET AL., J. ORG. CHEM., (1961), vol. 26, page 2525
    - CASTRO ET AL., TETRAHEDRON LETTERS, (1990), vol. 31, page 205
    - L. A. CARPINO, J. AMER. CHEM. SOC., (1993), vol. 115, page 4397
    - KONIG ET AL., CHEM. BER., vol. 103, no. 708, pages 2024 - 2034
    - MARY FIESER, Fiesers' Reagents for Organic Synthesis, JOHN WILEY, vol. 1-17
    - R. G. STRICKLY, "Solubilizing Excipients in oral and injectable formulations", PHARMACEUTICAL RESEARCH, (2004), vol. 21, no. 2, pages 201 - 230
    - J. CONTROL. RELEASE, (2003), vol. 91, no. 1-2, pages 167 - 172
    - SINHA ET AL., MOL. CANCER THER., (20060801), vol. 5, page 1909
    - BLASINA ET AL., MOL. CANCER THER., (2008), vol. 7, no. 8, pages 2394 - 2404
    - ASHWELL, CLIN. CANCER RES., (2008), vol. 14, no. 13, pages 4032 - 4037
    - ASHWELL ET AL., EXPERT OPIN. INVESTIG. DRUGS, (2008), vol. 17, no. 9, pages 1331 - 1340
    - TRENDS IN MOLECULAR MEDICINE, (201102), vol. 17, no. 2
    - CLIN CANCER RES, (20100115), vol. 16, no. 2
    - ASHWELL ET AL., CLIN. CANCER RES.
    - ALLRED, J. NAT. CANCER INSTITUTE, (1993), vol. 85, no. 3, pages 200 - 206
 WO2011GB00739
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.